6533b824fe1ef96bd1281626
RESEARCH PRODUCT
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.
L BartalenaLelio BaldeschiA DickinsonA EcksteinP Kendall TaylorClaudio MarcocciM MouritsP PerrosK BoboridisA BoschiN CurròC DaumerieGj KahalyGe KrassasCm LaneJh LazarusMichele Marino'Marco NardiC NeohJ OrgiazziS PearceAldo PincheraS PitzM SalviP SivelliM StahlG Von ArxWm Wiersinga European Group On Graves' Orbitopathysubject
medicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismGeneral surgeryMEDLINEGeneral Medicinemedicine.diseaseQuit smokingGraves' ophthalmopathyEuropeGraves OphthalmopathyEndocrinologyEndocrinologyEyelid surgeryInternal medicinePractice Guidelines as TopicmedicineHumansIn patientbusinessdescription
Summary of consensus a. All patients with GO should (Fig. 1):Be referred to specialist centers;Be encouraged to quit smoking;Receive prompt treatment in order to restore andmaintain euthyroidism.b. Patients with sight-threatening GO should be treatedwith i.v. GCs as the first-line treatment; if the responseis poor after 1–2 weeks, they should be submitted tourgent surgical decompression.c. The treatment of choice for moderate-to-severe GO isi.v. GCs (with or without OR) if the orbitopathy isactive;surgery(orbitaldecompression,squintsurgery,and/or eyelid surgery in this order) should beconsidered if the orbitopathy is inactive.d. In patients with mild GO, local measures and anexpectant strategy are sufficient in most cases, buttreatment may be justified if QoL is affectedsignificantly. In memoriam This document is dedicated to the memory of MarkPrummel (1956–2005), one of the founders ofEUGOGO, who greatly contributed to expanding ourunderstanding of clinical and therapeutic aspects of GO.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2008-01-01 | European journal of endocrinology |